Roche's Sefaxersen Shows 43% Proteinuria Reduction in Phase 3 IgA Nephropathy Study

New data from the Phase 3 IMAgINATION study, presented at a late-breaking oral session on October 23, 2026, revealed that investigational sefaxersen, an antisense therapy, achieved a 43.1% reduction in proteinuria in adults with primary IgA nephropathy (IgAN) on optimized standard of care. This significant reduction, coming on top of existing supportive therapy, is noteworthy as proteinuria is a validated surrogate marker for kidney function decline in IgAN.